Marina Adriana Mercioni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Adriana Mercioni has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Radu Dragomir
Department of Oncology, Victor Babes University of Medicine and Pharmacy Timisoara, E. Murgu Square, No. 2, 300041 Timisoara, Romania
6 shared publications - Adrian Goldiș
Department of Gastroenterology and Hepatology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
4 shared publications - Christian Goldiș
Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
4 shared publications - Ileana Enatescu
Discipline of Neonatology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
4 shared publications - Ion Petre
Department of Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
4 shared publications - Izabella Petre
Department XII of Obstetrics and Gynaecology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 2069
Interleukin-6, Proteinuria, and Arterial Stiffness in Preeclampsia: Distinct Inflammatory, Renal, and Vascular Associations
Background: Preeclampsia is characterized by systemic inflammation, endothelial dysfunction, and progressive abnormalities in the maternal vasculature. Interleukin-6 (IL-6) may indicate inflammatory activity, while aortic pulse wave velocity (PWVao) and augmentation index (AIx) offer complementary assessments of arterial stiffness and vascular function. This study examined the relationships among IL-6, proteinuria, and arterial stiffness in women with preeclampsia. Methods: This observational study involved 87 pregnant women with preeclampsia who were evaluated at the Emergency Clinical Hospital “Pius Brînzeu” in Timișoara, Romania. Arterial stiffness was measured non-invasively with the Arteriograph system during the second trimester (20–24 weeks) and the third trimester (32–36 weeks). PWVao served as the primary marker of arterial stiffness, whereas AIx provided a complementary measure of arterial wave reflection. Serum IL-6 levels were quantified by enzyme-linked immunosorbent assay, and 24 h proteinuria was recorded. Associations among inflammatory, renal, and vascular parameters were examined using Spearman correlation analyses. Multivariable linear regression then identified independent predictors of third-trimester PWVao. Results: The mothers had a mean age of 37.59 ± 2.65 years, and the mean BMI was 30.41 ± 2.70 kg/m2. PWVao rose significantly between the second and third trimesters, from 10.94 ± 1.36 m/s to 12.46 ± 1.70 m/s (p < 0.001). AIx also increased, from 1.26 ± 0.85% to 3.66 ± 1.32% (p < 0.001). The mean serum IL-6 concentration was 31.01 ± 35.61 pg/mL. No significant correlation was found between IL-6 and PWVao in either the second trimester (ρ = −0.100, p = 0.356) or the third trimester (ρ = −0.100, p = 0.358), and IL-6 was not significantly correlated with AIx. A significant positive correlation was observed between IL-6 and 24 h proteinuria (ρ = 0.337, p = 0.0014). Proteinuria itself showed no significant association with PWVao or AIx. In the multivariable analysis, only BMI independently predicted third-trimester PWVao (β = 0.634, 95% CI: 0.469–0.799, p < 0.001). Age, systolic blood pressure, proteinuria, and IL-6 showed no independent association with PWVao. Nor were IL-6, proteinuria, or third-trimester PWVao significantly associated with birth weight or the 1 min Apgar score. Conclusions: Among women with preeclampsia, arterial stiffness increased progressively throughout pregnancy. Systemic inflammation, measured by IL-6, was more strongly associated with renal involvement than with mechanical arterial stiffness. BMI was the main independent determinant of third-trimester PWVao. Together, these results support a multidimensional view of preeclampsia, in which inflammatory, renal, metabolic, and vascular abnormalities form related yet partly distinct pathways. Assessing IL-6, proteinuria, BMI, and arterial stiffness together may improve maternal cardiovascular phenotyping and help establish future risk-stratification strategies.
- 15 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 2069
Open AccessInterleukin-6, Proteinuria, and Arterial Stiffness in Preeclampsia: Distinct Inflammatory, Renal, and Vascular Associations
Background: Preeclampsia is characterized by systemic inflammation, endothelial dysfunction, and progressive abnormalities in the maternal vasculature. Interleukin-6 (IL-6) may indicate inflammatory activity, while aortic pulse wave velocity (PWVao) and augmentation index (AIx) offer complementary assessments of arterial stiffness and vascular function. This study examined the relationships among IL-6, proteinuria, and arterial stiffness in women with preeclampsia. Methods: This observational study involved 87 pregnant women with preeclampsia who were evaluated at the Emergency Clinical Hospital “Pius Brînzeu” in Timișoara, Romania. Arterial stiffness was measured non-invasively with the Arteriograph system during the second trimester (20–24 weeks) and the third trimester (32–36 weeks). PWVao served as the primary marker of arterial stiffness, whereas AIx provided a complementary measure of arterial wave reflection. Serum IL-6 levels were quantified by enzyme-linked immunosorbent assay, and 24 h proteinuria was recorded. Associations among inflammatory, renal, and vascular parameters were examined using Spearman correlation analyses. Multivariable linear regression then identified independent predictors of third-trimester PWVao. Results: The mothers had a mean age of 37.59 ± 2.65 years, and the mean BMI was 30.41 ± 2.70 kg/m2. PWVao rose significantly between the second and third trimesters, from 10.94 ± 1.36 m/s to 12.46 ± 1.70 m/s (p < 0.001). AIx also increased, from 1.26 ± 0.85% to 3.66 ± 1.32% (p < 0.001). The mean serum IL-6 concentration was 31.01 ± 35.61 pg/mL. No significant correlation was found between IL-6 and PWVao in either the second trimester (ρ = −0.100, p = 0.356) or the third trimester (ρ = −0.100, p = 0.358), and IL-6 was not significantly correlated with AIx. A significant positive correlation was observed between IL-6 and 24 h proteinuria (ρ = 0.337, p = 0.0014). Proteinuria itself showed no significant association with PWVao or AIx. In the multivariable analysis, only BMI independently predicted third-trimester PWVao (β = 0.634, 95% CI: 0.469–0.799, p < 0.001). Age, systolic blood pressure, proteinuria, and IL-6 showed no independent association with PWVao. Nor were IL-6, proteinuria, or third-trimester PWVao significantly associated with birth weight or the 1 min Apgar score. Conclusions: Among women with preeclampsia, arterial stiffness increased progressively throughout pregnancy. Systemic inflammation, measured by IL-6, was more strongly associated with renal involvement than with mechanical arterial stiffness. BMI was the main independent determinant of third-trimester PWVao. Together, these results support a multidimensional view of preeclampsia, in which inflammatory, renal, metabolic, and vascular abnormalities form related yet partly distinct pathways. Assessing IL-6, proteinuria, BMI, and arterial stiffness together may improve maternal cardiovascular phenotyping and help establish future risk-stratification strategies.
- Open Access
- 12 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1563
Machine Learning-Based Prediction of Treatment Response to Vitamin D3 in Adolescents and Young Adults with Inflammatory Bowel Disease: A Prospective, Open-Label, Alternation-Based Comparative Study
Background: Chronic inflammatory bowel diseases (IBDs), specifically Crohn’s disease and ulcerative colitis, present substantial clinical challenges characterized by a relapsing-remitting course. These conditions often lead to serious complications and significantly impair nutritional status, physical development, and overall quality of life. Methods: This unicentric, prospective, open-label, alternation-based comparative study investigated the efficacy of vitamin D3 supplementation in adolescents with IBD. Patients aged 15–25 years were randomly assigned to receive either 1000 IU/day or 2000 IU/day of cholecalciferol for 6 months as an adjuvant to standard care. Eighty patients completed the study. Results: By month 6, remission was achieved in 52.5% of patients receiving 1000 IU/day (Group A) and 87.5% of those receiving 2000 IU/day (Group B). Significant differences were observed between groups regarding disease activity (p = 0.007), C-reactive protein levels (30.17 ± 15.74 mg/L vs. 62.82 ± 37.14 mg/L; p < 0.001), and fecal calprotectin levels. Conclusions: The machine learning models demonstrated consistent performance in assessing inflammatory indicators, with a weighted average recall exceeding 72% (Random Forest: 82.50%). No adverse effects were reported. Supplementation with 2000 IU/day of vitamin D3 for 6 months was associated with more favorable clinical and biochemical outcomes than 1000 IU/day in this single-center open-label study as an adjunct to standard treatment in adolescents and young adults with IBD. The results suggest that higher doses of vitamin D may be beneficial in achieving remission and reducing systemic inflammation.
- 12 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1563
Open AccessMachine Learning-Based Prediction of Treatment Response to Vitamin D3 in Adolescents and Young Adults with Inflammatory Bowel Disease: A Prospective, Open-Label, Alternation-Based Comparative Study
Background: Chronic inflammatory bowel diseases (IBDs), specifically Crohn’s disease and ulcerative colitis, present substantial clinical challenges characterized by a relapsing-remitting course. These conditions often lead to serious complications and significantly impair nutritional status, physical development, and overall quality of life. Methods: This unicentric, prospective, open-label, alternation-based comparative study investigated the efficacy of vitamin D3 supplementation in adolescents with IBD. Patients aged 15–25 years were randomly assigned to receive either 1000 IU/day or 2000 IU/day of cholecalciferol for 6 months as an adjuvant to standard care. Eighty patients completed the study. Results: By month 6, remission was achieved in 52.5% of patients receiving 1000 IU/day (Group A) and 87.5% of those receiving 2000 IU/day (Group B). Significant differences were observed between groups regarding disease activity (p = 0.007), C-reactive protein levels (30.17 ± 15.74 mg/L vs. 62.82 ± 37.14 mg/L; p < 0.001), and fecal calprotectin levels. Conclusions: The machine learning models demonstrated consistent performance in assessing inflammatory indicators, with a weighted average recall exceeding 72% (Random Forest: 82.50%). No adverse effects were reported. Supplementation with 2000 IU/day of vitamin D3 for 6 months was associated with more favorable clinical and biochemical outcomes than 1000 IU/day in this single-center open-label study as an adjunct to standard treatment in adolescents and young adults with IBD. The results suggest that higher doses of vitamin D may be beneficial in achieving remission and reducing systemic inflammation.
- Open Access
Cervical Endometriosis Mimicking Microinvasive Cervical Carcinoma: A Diagnostic Pitfall and Literature Review
Background: Endometriosis of the cervix is a rare, non-cancerous disease that can look or behave like cancerous cervical tissue, causing challenges regarding diagnosis and management. Discrimination between benign and malignant lesions can be difficult when utilizing cytological, colposcopic, and histopathological data if the findings do not agree with each other. Case Presentation: We report the case of an asymptomatic 45-year-old woman who was initially diagnosed with FIGO stage IA1 microinvasive cervical carcinoma based on cytological, colposcopic, and conization findings. Further evaluation yielded persistent uncertainty in diagnostic imaging and, in addition, a concern for invasive cervical disease. Therefore, the patient underwent a total hysterectomy with bilateral salpingo-oophorectomy, and the result of the postoperative evaluation was cervical endometriosis without evidence of invasive malignancy. This example demonstrates the diagnostic challenges associated with rare benign cervical lesions, which may resemble cervical carcinoma, and emphasizes the high-risk for overtreatment due to the vagueness of these types of cases. Conclusions: When there is a discrepancy among clinical findings, cytology, and histopathology in suspicious cervical lesions, cervical endometriosis must be considered in the differential diagnosis. To increase accuracy in diagnosis and minimize the possibility of unnecessary radical treatment, careful histopathologic reevaluation and multidisciplinary assessment are necessary.
Open AccessCervical Endometriosis Mimicking Microinvasive Cervical Carcinoma: A Diagnostic Pitfall and Literature Review
Background: Endometriosis of the cervix is a rare, non-cancerous disease that can look or behave like cancerous cervical tissue, causing challenges regarding diagnosis and management. Discrimination between benign and malignant lesions can be difficult when utilizing cytological, colposcopic, and histopathological data if the findings do not agree with each other. Case Presentation: We report the case of an asymptomatic 45-year-old woman who was initially diagnosed with FIGO stage IA1 microinvasive cervical carcinoma based on cytological, colposcopic, and conization findings. Further evaluation yielded persistent uncertainty in diagnostic imaging and, in addition, a concern for invasive cervical disease. Therefore, the patient underwent a total hysterectomy with bilateral salpingo-oophorectomy, and the result of the postoperative evaluation was cervical endometriosis without evidence of invasive malignancy. This example demonstrates the diagnostic challenges associated with rare benign cervical lesions, which may resemble cervical carcinoma, and emphasizes the high-risk for overtreatment due to the vagueness of these types of cases. Conclusions: When there is a discrepancy among clinical findings, cytology, and histopathology in suspicious cervical lesions, cervical endometriosis must be considered in the differential diagnosis. To increase accuracy in diagnosis and minimize the possibility of unnecessary radical treatment, careful histopathologic reevaluation and multidisciplinary assessment are necessary.
- Open Access
- 4 May 2026
- Published by IntechOpen
Perspective Chapter: Machine Learning Models in Early Diagnosis and Risk Prediction of Skin Cancers
Skin cancer remains one of the most common malignancies worldwide, with early detection and personalised risk stratification being key to improving patient outcomes. In recent years, machine learning (ML) has emerged as a powerful tool in dermatology, offering enhanced diagnostic accuracy, risk prediction, and clinical decision-making as a support for clinicians and patients. This chapter investigates the current and future potential of ML models in the early diagnosis and prognostic modelling of pigmented skin cancers, including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). It examines the evolution of ML architectures, from classical algorithms like support vector machines and random forests to advanced convolutional neural networks (CNNs) and multi-module approaches. Key public datasets such as ISIC and HAM10000 are reviewed alongside their limitations, including the underrepresentation of Fitzpatrick skin types IV–VI. Through comprehensive tables and figures, we synthesise the performance metrics, learning methods, and datasets of leading diagnostic models. Furthermore, we highlight the integration of genomic data, mobile apps, FDA-cleared artificial intelligence (AI) devices, and real-time histopathology tools, as well as the ethical, technological, and regulatory challenges of clinical implementation. Data bias, privacy, and the need for inclusive design to ensure equity across diverse populations will also be discussed. The chapter concludes with a forward-looking perspective on federated learning, augmented reality (AR), and teledermatology (TD), aiming to shape an inclusive and AI-augmented future for skin cancer care.
- 4 May 2026
- Published by IntechOpen
Open AccessPerspective Chapter: Machine Learning Models in Early Diagnosis and Risk Prediction of Skin Cancers
Skin cancer remains one of the most common malignancies worldwide, with early detection and personalised risk stratification being key to improving patient outcomes. In recent years, machine learning (ML) has emerged as a powerful tool in dermatology, offering enhanced diagnostic accuracy, risk prediction, and clinical decision-making as a support for clinicians and patients. This chapter investigates the current and future potential of ML models in the early diagnosis and prognostic modelling of pigmented skin cancers, including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). It examines the evolution of ML architectures, from classical algorithms like support vector machines and random forests to advanced convolutional neural networks (CNNs) and multi-module approaches. Key public datasets such as ISIC and HAM10000 are reviewed alongside their limitations, including the underrepresentation of Fitzpatrick skin types IV–VI. Through comprehensive tables and figures, we synthesise the performance metrics, learning methods, and datasets of leading diagnostic models. Furthermore, we highlight the integration of genomic data, mobile apps, FDA-cleared artificial intelligence (AI) devices, and real-time histopathology tools, as well as the ethical, technological, and regulatory challenges of clinical implementation. Data bias, privacy, and the need for inclusive design to ensure equity across diverse populations will also be discussed. The chapter concludes with a forward-looking perspective on federated learning, augmented reality (AR), and teledermatology (TD), aiming to shape an inclusive and AI-augmented future for skin cancer care.
- 1 May 2026
- Published by Springer Nature
- p. 329-337
Evaluating Convolutional and Transformer-Based Deep Learning Models for Colorectal Cancer Tissue Recognition
- 1 May 2026
- Published by Springer Nature
- p. 329-337
Evaluating Convolutional and Transformer-Based Deep Learning Models for Colorectal Cancer Tissue Recognition
- Open Access
Images Versus Videos in Contrast-Enhanced Ultrasound for Computer-Aided Diagnosis
The background of the article refers to the diagnosis of focal liver lesions (FLLs) through contrast-enhanced ultrasound (CEUS) based on the integration of spatial and temporal information. Traditional computer-aided diagnosis (CAD) systems predominantly rely on static images, which limits the characterization of lesion dynamics. This study aims to assess the effectiveness of Transformer-based architectures in enhancing CAD performance within the realm of liver pathology. The methodology involved a systematic comparison of deep learning models for the analysis of CEUS images and videos. For image-based classification, a Hybrid Transformer Neural Network (HTNN) was employed. It combines Vision Transformer (ViT) modules with lightweight convolutional features. For video-based tasks, we evaluated a custom spatio-temporal Convolutional Neural Network (CNN), a CNN with Long Short-Term Memory (LSTM), and a Video Vision Transformer (ViViT). The experimental results show that the HTNN achieved an outstanding accuracy of 97.77% in classifying various types of FLLs, although it required manual selection of the region of interest (ROI). The video-based models produced accuracies of 83%, 88%, and 88%, respectively, without the need for ROI selection. In conclusion, the findings indicate that Transformer-based models exhibit high accuracy in CEUS-based liver diagnosis. This study highlights the potential of attention mechanisms to identify subtle inter-class differences, thereby reducing the reliance on manual intervention.
Open AccessImages Versus Videos in Contrast-Enhanced Ultrasound for Computer-Aided Diagnosis
The background of the article refers to the diagnosis of focal liver lesions (FLLs) through contrast-enhanced ultrasound (CEUS) based on the integration of spatial and temporal information. Traditional computer-aided diagnosis (CAD) systems predominantly rely on static images, which limits the characterization of lesion dynamics. This study aims to assess the effectiveness of Transformer-based architectures in enhancing CAD performance within the realm of liver pathology. The methodology involved a systematic comparison of deep learning models for the analysis of CEUS images and videos. For image-based classification, a Hybrid Transformer Neural Network (HTNN) was employed. It combines Vision Transformer (ViT) modules with lightweight convolutional features. For video-based tasks, we evaluated a custom spatio-temporal Convolutional Neural Network (CNN), a CNN with Long Short-Term Memory (LSTM), and a Video Vision Transformer (ViViT). The experimental results show that the HTNN achieved an outstanding accuracy of 97.77% in classifying various types of FLLs, although it required manual selection of the region of interest (ROI). The video-based models produced accuracies of 83%, 88%, and 88%, respectively, without the need for ROI selection. In conclusion, the findings indicate that Transformer-based models exhibit high accuracy in CEUS-based liver diagnosis. This study highlights the potential of attention mechanisms to identify subtle inter-class differences, thereby reducing the reliance on manual intervention.
- Open Access
- 7 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 336
Evaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania
Background and Objectives: As a leading European country in terms of cervical cancer incidence and mortality, there has been a pressing need for Romania to upgrade its cervical cancer management. The criteria set by the International Federation of Gynecology and Obstetrics indicate that different treatments should have a similar trend concerning progression-free survival and overall survival at all the various stages of cervical cancer. This study aimed to assess the cost-effectiveness (CE) of the primary treatment plans related to the survival rate for cervical cancer screening in the western part of Romania and provide some recommendations. Materials and Methods: Descriptive statistics and a correlation model were used to examine costs. AI models have been developed to forecast the CE of different treatments using the above-mentioned studies on overall survival rates and treatment-related toxicity rates for five years. The costs of cervical cancer treatment were sourced from the public health department, the oncology clinic in the western region of Romania, and the County Hospital available for each stage. Results: Treatment expenses vary by cancer stage, with a significant increase from stages IA/IB to IIA, stabilizing between IIA and IIIC (about €7800–€8300), followed by a steep decline in IVA and a more pronounced decrease in IVB and in situ. The results highlight certain treatment combinations and their costs, indicating that the highest costs (exceeding €8000) are linked to multimodal treatments, which encompass surgery, chemotherapy, radiotherapy, and brachytherapy. Conclusions: Advanced cancer stages (IIA–IIIC) entail the highest treatment costs due to intricate, multimodal therapy, whereas early stages (IA, IB, in situ) and late terminal stages (IVB) are linked to considerably reduced treatment costs.
- 7 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 336
Open AccessEvaluating the Cost-Effectiveness of Cervical Cancer Screening and Treatment in Western Romania
Background and Objectives: As a leading European country in terms of cervical cancer incidence and mortality, there has been a pressing need for Romania to upgrade its cervical cancer management. The criteria set by the International Federation of Gynecology and Obstetrics indicate that different treatments should have a similar trend concerning progression-free survival and overall survival at all the various stages of cervical cancer. This study aimed to assess the cost-effectiveness (CE) of the primary treatment plans related to the survival rate for cervical cancer screening in the western part of Romania and provide some recommendations. Materials and Methods: Descriptive statistics and a correlation model were used to examine costs. AI models have been developed to forecast the CE of different treatments using the above-mentioned studies on overall survival rates and treatment-related toxicity rates for five years. The costs of cervical cancer treatment were sourced from the public health department, the oncology clinic in the western region of Romania, and the County Hospital available for each stage. Results: Treatment expenses vary by cancer stage, with a significant increase from stages IA/IB to IIA, stabilizing between IIA and IIIC (about €7800–€8300), followed by a steep decline in IVA and a more pronounced decrease in IVB and in situ. The results highlight certain treatment combinations and their costs, indicating that the highest costs (exceeding €8000) are linked to multimodal treatments, which encompass surgery, chemotherapy, radiotherapy, and brachytherapy. Conclusions: Advanced cancer stages (IIA–IIIC) entail the highest treatment costs due to intricate, multimodal therapy, whereas early stages (IA, IB, in situ) and late terminal stages (IVB) are linked to considerably reduced treatment costs.
- Open Access
Clinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory Bowel Disease
Background: Few studies have evaluated the efficacy of butyric acid in treating children with inflammatory bowel disease (IBD). In children and adolescents with recently diagnosed IBD, the purpose of this research was to assess the efficacy of oral sodium butyrate (the product-patented, sustained and targeted-release form of butyrate MSB®) as an adjunct to conventional treatment. Methods: This trial was unicentric, prospective, randomized, and placebo-controlled. An amount of 150 mg sodium butyrate once a day (Group A), or a placebo (Group B) were randomly assigned to patients with ulcerative colitis or Crohn’s disease, aged 7–18 years, who were receiving conventional medication based on the severity of their conditions. Disease activity, C-reactive protein (CRP), and fecal calprotectin concentration differences between the two study groups at 12 weeks of the trial were the main outcomes. Results: With 44 patients in Group A and 44 in Group B, 88 individuals with initially active illness finished the research. Most patients experienced remission by week 12 of the study (36 patients in Group A with sodium butyrate, 81.82%; 21 patients in Group B with placebo, 47.73%). Between the two groups, a significant difference in disease activity was seen (p < 0.001). The sodium butyrate group appeared to have less systemic inflammation than the other group, as evidenced by the significantly lower CRP levels in Group A (18.14 ± 11.19 mg/L) compared to Group B (57.00 ± 33.28 mg/L) at 12 weeks (T2) (p < 0.001). No negative effects were recorded by any of the patients. Fecal calprotectin in Group A dropped much more after 12 weeks (T2) (p < 0.001), suggesting that the sodium butyrate group was better able to regulate intestinal inflammation. Conclusions: In newly diagnosed children and adolescents with IBD, a 12-week sodium butyrate supplementation did demonstrate effectiveness as an additional treatment.
Open AccessClinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory Bowel Disease
Background: Few studies have evaluated the efficacy of butyric acid in treating children with inflammatory bowel disease (IBD). In children and adolescents with recently diagnosed IBD, the purpose of this research was to assess the efficacy of oral sodium butyrate (the product-patented, sustained and targeted-release form of butyrate MSB®) as an adjunct to conventional treatment. Methods: This trial was unicentric, prospective, randomized, and placebo-controlled. An amount of 150 mg sodium butyrate once a day (Group A), or a placebo (Group B) were randomly assigned to patients with ulcerative colitis or Crohn’s disease, aged 7–18 years, who were receiving conventional medication based on the severity of their conditions. Disease activity, C-reactive protein (CRP), and fecal calprotectin concentration differences between the two study groups at 12 weeks of the trial were the main outcomes. Results: With 44 patients in Group A and 44 in Group B, 88 individuals with initially active illness finished the research. Most patients experienced remission by week 12 of the study (36 patients in Group A with sodium butyrate, 81.82%; 21 patients in Group B with placebo, 47.73%). Between the two groups, a significant difference in disease activity was seen (p < 0.001). The sodium butyrate group appeared to have less systemic inflammation than the other group, as evidenced by the significantly lower CRP levels in Group A (18.14 ± 11.19 mg/L) compared to Group B (57.00 ± 33.28 mg/L) at 12 weeks (T2) (p < 0.001). No negative effects were recorded by any of the patients. Fecal calprotectin in Group A dropped much more after 12 weeks (T2) (p < 0.001), suggesting that the sodium butyrate group was better able to regulate intestinal inflammation. Conclusions: In newly diagnosed children and adolescents with IBD, a 12-week sodium butyrate supplementation did demonstrate effectiveness as an additional treatment.
- Open Access
- 30 April 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 1047
Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach
Inflammatory bowel disease (IBD) is a complex disorder influenced by genetic, environmental, and microbial factors, with emerging evidence highlighting the gut microbiome’s role in disease pathogenesis. This study investigates the impact of microbiome-targeted interventions in pediatric IBD by integrating multi-omics analysis, including metagenomics, metabolomics, transcriptomics, and clinical biomarkers, to identify microbial dysbiosis patterns and potential therapeutic targets. A cohort of pediatric IBD patients underwent a personalized intervention involving dietary modifications, probiotic supplementation, and selective antibiotic therapy. Microbiome composition, inflammatory markers (fecal calprotectin, CRP), and disease activity scores (PCDAI/PUCAI) were assessed before and after treatment. At the 3-month follow-up, patients showed significant clinical improvement, with reduced stool frequency (p = 0.004) and improved stool consistency (p < 0.001). Symptoms such as bloating and abdominal pain decreased, while energy levels increased (p < 0.001). Dietary changes included higher fruit, meat, and dairy intake, and lower fast-food and sweets consumption (p < 0.001). Physician assessments classified 90% as “improved”, reinforcing the effectiveness of personalized microbiome interventions. Microbiome-targeted interventions (diet, probiotics, and selective antibiotics) improved pediatric IBD outcomes by reducing pathogenic bacteria and increasing short-chain fatty acid (SCFA)-producing species, lowering inflammation and symptoms. Early-life factors (cesarean birth, and formula feeding) influence IBD risk. Personalized diets enhanced microbial balance. Integrating multi-omics supports precision medicine, offering microbiome-based biomarkers and reducing immunosuppressive reliance.
- 30 April 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (5) , 1047
Open AccessPersonalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach
Inflammatory bowel disease (IBD) is a complex disorder influenced by genetic, environmental, and microbial factors, with emerging evidence highlighting the gut microbiome’s role in disease pathogenesis. This study investigates the impact of microbiome-targeted interventions in pediatric IBD by integrating multi-omics analysis, including metagenomics, metabolomics, transcriptomics, and clinical biomarkers, to identify microbial dysbiosis patterns and potential therapeutic targets. A cohort of pediatric IBD patients underwent a personalized intervention involving dietary modifications, probiotic supplementation, and selective antibiotic therapy. Microbiome composition, inflammatory markers (fecal calprotectin, CRP), and disease activity scores (PCDAI/PUCAI) were assessed before and after treatment. At the 3-month follow-up, patients showed significant clinical improvement, with reduced stool frequency (p = 0.004) and improved stool consistency (p < 0.001). Symptoms such as bloating and abdominal pain decreased, while energy levels increased (p < 0.001). Dietary changes included higher fruit, meat, and dairy intake, and lower fast-food and sweets consumption (p < 0.001). Physician assessments classified 90% as “improved”, reinforcing the effectiveness of personalized microbiome interventions. Microbiome-targeted interventions (diet, probiotics, and selective antibiotics) improved pediatric IBD outcomes by reducing pathogenic bacteria and increasing short-chain fatty acid (SCFA)-producing species, lowering inflammation and symptoms. Early-life factors (cesarean birth, and formula feeding) influence IBD risk. Personalized diets enhanced microbial balance. Integrating multi-omics supports precision medicine, offering microbiome-based biomarkers and reducing immunosuppressive reliance.
- Open Access
- 26 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 795
Introducing a Novel Personalized Microbiome-Based Treatment for Inflammatory Bowel Disease: Results from NostraBiome’s Internal Validation Study
Background/Objectives: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is characterized by chronic gut inflammation driven by microbial dysbiosis and immune dysfunction. Current therapies primarily involve anti-inflammatory and immunomodulatory strategies; however, many patients experience an inadequate response or a gradual loss of efficacy over time. This study evaluates the clinical efficacy of personalized microbiome modulation (PMM)—an AI-driven intervention designed to restore microbial balance and improve key treatment outcomes such as symptom control and remission rates. Methods: This was a single-arm, open-label validation trial involving 27 patients with moderate-to-severe IBD who had experienced prior treatment failure. Participants underwent three months of PMM, which included personalized dietary modifications, targeted probiotic supplementation, and antimicrobial interventions based on gut microbiome sequencing. Primary outcomes included stool frequency and consistency as well as inflammatory markers (C-reactive protein and fecal calprotectin), while secondary outcomes assessed nutritional status, metabolic function, and quality of life. Statistical analyses included paired t-tests and repeated measures ANOVA to determine significant changes over time. Results: PMM led to significant clinical improvements, including a 58% reduction in stool frequency (p < 0.001) and improved stool consistency. CRP and fecal calprotectin levels decreased markedly (p < 0.001), suggesting reduced systemic inflammation. Additionally, iron, vitamin B12, and vitamin D deficiencies improved (p < 0.001), alongside weight gain and increased energy levels. Notably, patients on anti-TNF biologics showed enhanced response rates, suggesting potential synergistic effects between microbiome modulation and biologic therapy. Conclusions: This study highlights PMM as a promising adjunctive therapy for IBD, demonstrating benefits across clinical, inflammatory, and metabolic parameters. While findings support the role of microbiome-targeted interventions in disease management, larger randomized controlled trials are required to confirm the long-term efficacy and applicability in broader patient populations.
- 26 March 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 795
Open AccessIntroducing a Novel Personalized Microbiome-Based Treatment for Inflammatory Bowel Disease: Results from NostraBiome’s Internal Validation Study
Background/Objectives: Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is characterized by chronic gut inflammation driven by microbial dysbiosis and immune dysfunction. Current therapies primarily involve anti-inflammatory and immunomodulatory strategies; however, many patients experience an inadequate response or a gradual loss of efficacy over time. This study evaluates the clinical efficacy of personalized microbiome modulation (PMM)—an AI-driven intervention designed to restore microbial balance and improve key treatment outcomes such as symptom control and remission rates. Methods: This was a single-arm, open-label validation trial involving 27 patients with moderate-to-severe IBD who had experienced prior treatment failure. Participants underwent three months of PMM, which included personalized dietary modifications, targeted probiotic supplementation, and antimicrobial interventions based on gut microbiome sequencing. Primary outcomes included stool frequency and consistency as well as inflammatory markers (C-reactive protein and fecal calprotectin), while secondary outcomes assessed nutritional status, metabolic function, and quality of life. Statistical analyses included paired t-tests and repeated measures ANOVA to determine significant changes over time. Results: PMM led to significant clinical improvements, including a 58% reduction in stool frequency (p < 0.001) and improved stool consistency. CRP and fecal calprotectin levels decreased markedly (p < 0.001), suggesting reduced systemic inflammation. Additionally, iron, vitamin B12, and vitamin D deficiencies improved (p < 0.001), alongside weight gain and increased energy levels. Notably, patients on anti-TNF biologics showed enhanced response rates, suggesting potential synergistic effects between microbiome modulation and biologic therapy. Conclusions: This study highlights PMM as a promising adjunctive therapy for IBD, demonstrating benefits across clinical, inflammatory, and metabolic parameters. While findings support the role of microbiome-targeted interventions in disease management, larger randomized controlled trials are required to confirm the long-term efficacy and applicability in broader patient populations.